The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective
Abstract
The lung is a complex organ; it is both the initial barrier for inhaled agents and the site of metabolism and therapeutic effect for a subset of systemically administered drugs. Comprised of more than 40 cell types that are responsible for various important functions, the lung's complexity contributes to the subsequent challenges in developing complex in vitro co-culture models (also called microphysiological systems (MPS), complex in vitro models or organs-on-a-chip). Although there are multiple considerations and limitations in the development and qualification of such in vitro systems, MPS exhibit great promise in the fields of pharmacology and toxicology. Successful development and implementation of MPS models may enable mechanistic bridging between non-clinical species and humans, and increase clinical relevance of safety endpoints, while decreasing overall animal use. This article summarizes, from a biopharmaceutical industry perspective, essential elements for the development and qualification of lung MPS models. Its purpose is to guide MPS developers and manufacturers to expedite MPS utilization for safety assessment in the biopharmaceutical industry.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These consortia not only promote MPS and OoC adoption but also generate lists of reference compounds relevant to various organ systems (Ainslie et al., 2019; Baudy et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Phillips et al., 2020; Pointon et al., 2021).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Ainslie et al., 2019
Citations
Cites
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
Huh, D., Leslie, D. C., Matthews, B. D., Fraser, J. P., Jurek, S., Hamilton, G. A., Thorneloe, K. S., McAlexander, M. A., & Ingber, D. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004249 · Cited by 993
Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro
Benam, K. H., Villenave, R., Lucchesi, C., Varone, A., Hubeau, C., Lee, H.-H., Alves, S. E., Salmon, M., Ferrante, T. C., Weaver, J. C., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3697 · Cited by 816
Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids
Kasendra, M., Tovaglieri, A., Sontheimer-Phelps, A., Jalili-Firoozinezhad, S., Bein, A., Chalkiadaki, A., Scholl, W., Zhang, C., Rickner, H., Richmond, C. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21201-7 · Cited by 754
Lee, J.-H., Bhang, D. H., Beede, A., Huang, T. L., Stripp, B. R., Bloch, K. D., Wagers, A. J., Tseng, Y.-H., Ryeom, S., & Kim, C. F. (2014) · Cell · doi:10.1016/j.cell.2013.12.039 · Cited by 490
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Research works printed but not linked: 4
- Marx, 2016, ALTEX, 33, 272
- N. Sachs , D. D. Z.Ommen , A.Papaspyropoulos , I.Heo , L.Bottinger , D.Klay , F.Weeber , G.Huelsz-Prince , N.Iakobachvili , M. C.Viveen , A.Lyubimova , L.Teeven , S.Derakhshan , J.Korving , H.Begthel , K.Kumawat , E.Ramos , M. F. M.van Oosterhout , E. P.Olimpio , J.de Ligt , K. K.Dijkstra , E. F.Smit , M.van der Linden , E. E.Voest , C. H. M.van Moorsel , C. K.van der Ent , E.Cuppen , A.van Oudenaarden , F. E.Coenjaerts , L.Meyaard , L. J.Bont , P. J.Peters , S. J.Tans , J. S.van Zon , S. F.Boj , R. G.Vries , J. M.Beekman and H.Clevers , bioRxiv, 2018 , p. 318444
- Ralston, 2017, Toxicologist, 150, 312
- Fagan, 2011, US Pharm., 36, HS3
Cited by
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Si, L., Bai, H., Rodas, M., Cao, W., Oh, C. Y., Jiang, A., Moller, R., Hoagland, D., Oishi, K., Horiuchi, S., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00718-9 · Cited by 440
“…physiologically relevant organ-level features of lung, such as mucus layer formation, mucociliary clearance, cross-talk between epithelium and endothelium, or recruitment of circulating immune cells 10,11 , all of which play key roles in host responses to infection by respiratory viruses 10,11,15 .”
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Marx, U. (2020) · ALTEX · doi:10.14573/altex.2001241 · Cited by 218
“Members of the IQ Consortium recently published recommendations for in vitro model development and assay qualification of lung and skin models to facilitate their wider adoption for use within the pharmaceutical industry (Ainslie et al., 2019; Hardwick et al., 2019).”
MethodOrgans-on-chips technologies – A guide from disease models to opportunities for drug development
Monteduro, A. G., Rizzato, S., Caragnano, G., Trapani, A., Giannelli, G., & Maruccio, G. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115271 · Cited by 175
Fabre, K., Berridge, B., Proctor, W. R., Ralston, S., Will, Y., Baran, S. W., Yoder, G., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc01168d · Cited by 116
Self-citationFowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 109
Towards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Innovative preclinical models for pulmonary drug delivery research
Ehrmann, S., Schmid, O., Darquenne, C., Rothen‐Rutishauser, B., Sznitman, J., Yang, L., Barošová, H., Vecellio, L., Mitchell, J. P., & Heuzé‐Vourc'h, N. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1730807 · Cited by 82
“Such efforts have been motivated by the need to move beyond the limitations of traditional cell culture and concurrently tackle the limitations of in-vivo animal models for clinical relevance [87]; a point that hasbeenmost recently highlighted in a seminal review emanating froma consortiumof leading pharmaceutical pla…”
BackgroundApplication of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Doryab, A., Taskin, M. B., Stahlhut, P., Schröppel, A., Orak, S., Voss, C., Ahluwalia, A. D., Rehberg, M., Hilgendorff, A., Stöger, T., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.616830 · Cited by 60
“This has led the way from mono-cellular submerged cell lines to primary co-culture cell models at the ALI (air-blood barrier), from static cell culture media and cell layers to medium perfusion (pulmonary blood flow) and cyclic stretch (breathing-induced mechanical tissue strain), and from millifluidic (∼cm2 cell area…”
Yang, S., Zhang, T., Ge, Y., Cheng, Y., Yin, L., Pu, Y., Chen, Z., & Liang, G. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.131962 · Cited by 65
Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemicsPreprint
Si, L., Bai, H., Rodas, M. J., Cao, W., Oh, C. Y., Jiang, A. R., Møller, R., Hoagland, D. A., Oishi, K., Horiuchi, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.13.039917 · Cited by 59
Yang, S., Chen, Z., Cheng, Y., Liu, T., Yin, L., Pu, Y., & Liang, G. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.115861 · Cited by 61
Sengupta, A., Roldán, N., Kiener, M., Froment, L., Raggi, G., Imler, T., Maddalena, L. L. D., Rapet, A., May, T., Carius, P., et al. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.840606 · Cited by 62
“Particularly in the industrial setting, cell line-based organs-on-chip such as the iAECs on-Lung-on-chip represent a path forward to provide qualified models with higher throughput, robustness, and automatization opportunities, which are essential factors for the standardization and validation of this technology with…”
BackgroundOuédraogo, G., Alépée, N., Tan, B., & Roper, C. S. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105904 · Cited by 64
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2021) · Cells Tissues Organs · doi:10.1159/000517422 · Cited by 62
“…including the kidney, liver, skin, lung, cardiovascular, blood-brain barrier, and gastrointestinal systems, as well as for ADME applications [Ainslie et al., 2019; Baudy et al., 2020; Fabre et al., 2020; Fowler et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Peterson et al., 2020;…”
BackgroundApplicability of organ-on-chip systems in toxicology and pharmacology
Schneider, M. R., Oelgeschläger, M., Burgdorf, T., van Meer, P. J. K., Theunissen, P. T., Kienhuis, A. S., Piersma, A. H., & Vandebriel, R. J. (2021) · Critical Reviews in Toxicology · doi:10.1080/10408444.2021.1953439 · Cited by 52
Veliz, D. S., Lin, K.-L., & Sahlgren, C. (2023) · Smart Medicine · doi:10.1002/smmd.20220030 · Cited by 22
Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics
Artzy‐Schnirman, A., Raviv, S. A., Doppelt‐Flikshtain, O., Shklover, J., Korin, N., Gross, A., Mizrahi, B., Schroeder, A., & Sznitman, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113901 · Cited by 48
“By and large, most lung on-chips have generally focused on designs of individual isolated airway channels that forego the detailed acinar topology [5,7,36,114].”
BackgroundKopec, A. K., Yokokawa, R., Khan, N., Horii, I., Finley, J. E., Bono, C. P., Donovan, C. B., Roy, J., Harney, J. A., Burdick, A. D., et al. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.99 · Cited by 44
“Additional details regarding desirable characteristics of lung MPS models have been carefully reviewed by Ainslie et al. (2019).”
Advances of microfluidic lung chips for assessing atmospheric pollutants exposure
Wang, H., Yin, F., Li, Z., Su, W., & Li, D. (2023) · Environment International · doi:10.1016/j.envint.2023.107801 · Cited by 43
Baker, T. K., Vleet, T. R. V., Mahalingaiah, P. K. S., Grandhi, T. S. P., Evers, R., Ekert, J. E., Gosset, J. R., Chacko, S. A., & Kopec, A. K. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001510 · Cited by 42
Nof, E., Zidan, H., Artzy‐Schnirman, A., Mouhadeb, O., Beckerman, M., Bhardwaj, S., Elias‐Kirma, S., Gur, D., Beth-Din, A., Levenberg, S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.853317 · Cited by 36
Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300131 · Cited by 33
Reconstruction of Ultra‐thin Alveolar‐capillary Basement Membrane Mimics
Jain, P., Nishiguchi, A., Linz, G., Weßling, M., Ludwig, A., Rossaint, R., Möller, M., & Singh, S. (2021) · Advanced Biology · doi:10.1002/adbi.202000427 · Cited by 32
Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
Ramamurthy, R. M., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011143 · Cited by 36
Microphysiological systems: What it takes for community adoption
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211008872 · Cited by 35
Jiménez-Valdés, R. J., Can, U. I., Niemeyer, B. F., & Benam, K. H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00989 · Cited by 31
“During formation, organoids develop into 3D tissues that recreate in vivo-observed microanatomy through self-organization (Fang and Eglen, 2017; Ainslie et al., 2019).”
BackgroundInfluentialMovia, D., & Prina‐Mello, A. (2020) · Animals · doi:10.3390/ani10081259 · Cited by 31
Ugodnikov, A., Persson, H., & Simmons, C. A. (2024) · Lab on a Chip · doi:10.1039/d3lc01027a · Cited by 32
Richter, C., Latta, L., Harig, D., Carius, P., Stucki, J. D., Hobi, N., Hugi, A., Schumacher, P., Krebs, T., Gamrekeli, A., et al. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10715 · Cited by 25
“2,19 Two main anatomical areas of the human lung can be discerned: the conducting airways, consisting mainly of bronchi of gradually decreasing diameter, and the respiratory area in the deep lung, formed by the alveoli.”
Advances in microfluidic 3D cell culture for preclinical drug development
(2022) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2021.07.022 · Cited by 23
Kanabekova, P., Dauletkanov, B., Bekezhankyzy, Z., Toktarkan, S., Martin, A., Pham, T. T., Κώστας, Κ., & Kulsharova, G. (2023) · Lab on a Chip · doi:10.1039/d3lc00751k · Cited by 23
Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project
Ishida, S. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.657765 · Cited by 29
“The discussions that took place within this forum have been summarized and published in several reviews within the last 2 years (Ainslie et al., 2019; Baudy et al., 2019; Fabre et al., 2019; Fowler et al., 2019; Hardwick et al., 2019; Philips et al., 2019).”
BackgroundThe Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhou, Z., Zhu, J., Jiang, M., Sang, L., Hao, K., & He, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050704 · Cited by 23
A Model of Human Small Airway on a Chip for Studies of Subacute Effects of Inhalation Toxicants
Sakolish, C., Georgescu, A., Huh, D., & Rusyn, I. (2022) · Toxicological Sciences · doi:10.1093/toxsci/kfac036 · Cited by 21
Complex in vitro models positioned for impact to drug testing in pharma: a review
Kang, S., Chen, E. C., Cifuentes, H., Co, J. Y., Cole, G., Graham, J. C., Hsia, I., Kiyota, T., Klein, J. A., Kroll, K. T., et al. (2024) · Biofabrication · doi:10.1088/1758-5090/ad6933 · Cited by 24
“…and iPSC-derived [140] organoid models of lung diseases have been used to screen a large number of drugs for their therapeutic efficacy, very few studies [108, 110, 111, 141] have performed COU assays in in vitro healthy lung models to determine their predictive value for safety or disposition.”
Artzy‐Schnirman, A., Lehr, C., & Sznitman, J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1738380 · Cited by 23
Carius, P., Dubois, A., Ajdarirad, M., Artzy‐Schnirman, A., Sznitman, J., Schneider‐Daum, N., & Lehr, C. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.743236 · Cited by 19
Culturing the unculturables: strategies, challenges, and opportunities for gut microbiome study
Yadav, A., Ahlawat, S., & Sharma, K. K. (2023) · Journal of Applied Microbiology · doi:10.1093/jambio/lxad280 · Cited by 21
Towards an artificial human lung: modelling organ-like complexity to aid mechanistic understanding
Humbert, M. V., Spalluto, C. M., Bell, J., Blume, C., Conforti, F., Davies, E. R., Dean, L. S. N., Elkington, P. T., Haitchi, H. M., Jackson, C. L., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00455-2022 · Cited by 21
Padmyastuti, A., Sarmiento, M. G., Dib, M., Ehrhardt, J., Schoon, J., Somova, M., Burchardt, M., Roennau, C., & Pinto, P. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-38834-y · Cited by 17
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities
Maulana, T. I., Wevers, N. R., Kristoforus, T., Chandler, M. R., Lanz, H. L., Joore, J., Vulto, P., Villenave, R., Kustermann, S., Loskill, P., et al. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080621 · Cited by 24
Progress and application of lung-on-a-chip for lung cancer
Li, L., Bo, W., Wang, G., Juan, X., Xue, H., & Zhang, H. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1378299 · Cited by 18
Organ-On-A-Chip Database Revealed—Achieving the Human Avatar in Silicon
Jiang, L., Li, Q., Liang, W., Du, X., Yang, Y., Zhang, Z., Xu, L., Zhang, J., Li, J., Chen, Z., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9110685 · Cited by 17
“Firstly, OOCs can be classified according to their simulated organs, for instance, Liveron-Chips [19,20], Brain-on-Chips [21–23], Cardiac-on-Chips [24,25], Bone-on-Chips [26,27], Kidney-on-Chips [28], Lung-on-Chips [2,29], Muscle-on-Chips [30], Intestine-on-Chips [31,32], Skin-on-Chips [33–35], and Multiple-Organs-on-…”
BackgroundMicrofluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study
Wang, H., Wen, T., Zhu, W., Li, K., Gong, X., & Li, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100905 · Cited by 18
“Besides, more complex cell types such as lung epithelium, microvascular endothelium, microbes, and immune cells can be cocultured in the same system, with different design types [20].”
BackgroundGan, J., Bolon, B. N., Vleet, T. V., & Wood, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00005-4 · Cited by 15
Weener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1513002 · Cited by 10
Yamazaki, D., & Ishida, S. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101047 · Cited by 11
Xie, X., Zhao, J., Liu, T., Lü, L., Qin, Y., Song, X., Ge, Y., & Zhao, J. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134282 · Cited by 10
Mera: A scalable high throughput automated micro-physiological system
Cliffe, F. E., Madden, C., Costello, P., Devitt, S., Mukkunda, S. R., Keshava, B. B., Fearnhead, H. O., Vitkauskaite, A., Dehkordi, M. H., Chingwaru, W., et al. (2023) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2023.01.004 · Cited by 8
Opportunities for Biomanufacturing in Low Earth Orbit: Current Status and Future DirectionsPreprint
Giulianotti, M. A., Sharma, A., Clemens, R. A., Garcia, O., Taylor, L., Wagner, N. L., Shepard, K. A., Gupta, A., Malany, S., Grodzinsky, A. J., et al. (2021) · Preprints.org · doi:10.20944/preprints202108.0044.v1 · Cited by 7
Assessment of drug permeability using a small airway microphysiological system
Geiger, R. M., Rahman, S. M., Roni, M. S. R., Sullenberger, C., Mistry, S., Shea, K. I., Tariq, I., Ismaiel, O. A., Matta, M. K., Hyland, P. L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1621775 · Cited by 6
LaFollette, M. R., Baran, S. W., Curley, J. L., Dickinson, A. M., Frazier, T. P., Hobi, N., Huang, M.-I., Hutter, V., Maisonneuve, B. G. C., Marsh, G., et al. (2025) · Alternatives to Laboratory Animals · doi:10.1177/02611929241310566 · Cited by 5
Hu, Z., Xu, Y.-E., Li, J. M., Wang, Y., Song, H. Y., & Ao, D.-S. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00290g · Cited by 3
The Role of Advanced Technologies against COVID-19: Prevention, Detection, and Treatments
Hasanzadeh, E., Rafati, A., Tamijani, S. M. S., Rafaiee, R., Golchin, A., & Abasi, M. (2022) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666221221123505 · Cited by 3
Rindchen, A., Schneider‐Daum, N., & Lehr, C. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115917 · Cited by 3
Cell-based in vitro models for pulmonary permeability studies
Richter, C., Neu, T., Latta, L., Schneider‐Daum, N., & Lehr, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15510-9.00009-8 · Cited by 1
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Somova, M., Grosse, M., Schulze, F., Burchardt, M., & Caetano-Pinto, P. (2025) · Journal of Visualized Experiments · doi:10.3791/67456 · Cited by 1
Toxicity Testing In Vitro. Regulatory Aspects
von Keutz, E. (2021) · Springer eBooks · doi:10.1007/978-3-642-36206-4_35-2 · Cited by 1
Toxicity Testing In Vitro: Regulatory Aspects
von Keutz, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-57499-4_35 · Cited by 1
Development of Biomimetic Human Lung Alveolus Chip
Man, K. (2023) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2137604
WITHDRAWN: Mera: A scalable high throughput automated micro-physiological system
Cliffe, F. E., Madden, C., Costello, P., Devitt, S., Mukkunda, S. R., Keshava, B. B., Fearnhead, H. O., Vitkauskaite, A., Dehkordi, M. H., Chingwaru, W., et al. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.006
RetractedModeling Transport and Biomechanics of Pulmonary Capillary Networks in Health and Disease
Amar, D. N., Glozman, A., Sznitman, J., & Korin, N. (2025) · Journal of Biomechanical Engineering · doi:10.1115/1.4069592 · Cited by 1
Metadata
- Authors
- Ainslie, G. R., Davis, M., Ewart, L., Lieberman, L. A., Rowlands, D. J., Thorley, A. J., Yoder, G., & Ryan, A. M.
- Affiliations
- Theravance Biopharma (United States) (US)
- Princeton University (US)
- AstraZeneca (United Kingdom) (GB)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Novartis (Switzerland) (CH)
- Janssen (Belgium) (BE)
- Pfizer (United States) (US)
- Corresponding author
- Ainslie, Garrett R.
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 19
- Issue
- 19
- Pages
- 3152-3161
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- OpenAlex
- W2970730415
- Cited by
- 65
- References
- 33
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 9 · 2021: 15 · 2020: 10
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lab on a Chip (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Institutes for BioMedical Research
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- microphysiological systems, lung-on-a-chip, in vitro co-culture model, drug safety assessment, toxicology, model qualification, animal use reduction, biopharmaceutical development
- MeSH terms
- Humans, Lung, Models, Biological, Coculture Techniques, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.